Company news

Cardiff Oncology, Inc. news in 2026

Cardiff Oncology, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer

October 27, 2026

Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia

October 21, 2026

Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement

September 14, 2026

Cardiff Oncology to Participate in September 2026 Conferences

September 2, 2026

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

August 11, 2026

Cardiff Oncology Announces $10 Million Registered Direct Offering

July 15, 2026

Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting

June 2, 2026

Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference

June 1, 2026

Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC

May 21, 2026

Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update

May 14, 2026

Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity

April 27, 2026

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

April 17, 2026

Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth

April 8, 2026

Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer

March 20, 2026

Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting

March 18, 2026

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

February 26, 2026

Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

February 24, 2026

Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 18, 2026

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

January 27, 2026

Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

January 27, 2026

Decks in 2026